Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers
Sugier, Pierre‐Emmanuel , Lucotte, Elise A. , Domenighetti, Cloé , Law, Matthew H. , Iles, Mark M. , Brown, Kevin M. , McKay, James , Hung, Rayjean J., Karimi, Mojgan, Bacq‐Daian, Delphine, Boland, Anne , Kesminiene, Ausrele , Vathaire, Florent de , Guénel, Pascal , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Hung, Rayjean J. , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Zimprich, Alexander , Lang, Anthony E , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Deutschländer, Angela B , Hadjigeorgiou, Georges M., Stefanis, Leonidas , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Hung, Rayjean J , Puschmann, Andreas , Guénel, Pascal , Law, Matthew H , Iles, Mark M , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Amos, Christopher I. , Olaso, Robert , Deleuze, Jean‐François , Lesueur, Fabienne , Ostroumova, Evgenia , Schulte, Claudia , Bobbili, Dheeraj Reddy , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Dardiotis, Efthimios , Simitsi, Athina‐Maria , Valente, Enza Maria , Zecchinelli, Anna , Pezzoli, Gianni , Gagliardi, Monica , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Farrer, Matthew J. , Truong, Thérèse , Elbaz, Alexis

Mayo Clinic

Movement Disorders | February 14, 2023 | Volume: 38 | Issue: 4 | Pages: 604-615

10.1002/mds.29337 | PMID 36788297 Get It

Abstract Background Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties. Objective We used results from genome‐wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors. Methods We used individual data for participants of European ancestry from the Courage‐PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta‐Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa, using cross‐phenotypes polygenic risk score (PRS) analyses. Results We confirmed a previously reported positive genetic correlation of PD with melanoma (G corr = 0.16 [0.04; 0.28]) and reported an additional significant positive correlation of PD with prostate cancer (G corr = 0.11 [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the NSF gene (17q21.31). Conclusions We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Transplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases
Azar, Marwan M. , Tsai, Helen , Vergidis, Paschalis , Harris, Courtney E. , Anjan, Shweta , Barros, Nicolas , Belga, Sara , Chuang, Sally T, Czeresnia, Jonathan Mamber , Goel, Shipra , İnce, Dilek , Luk, Alfred , Obeid, Karam M. , Swaminathan, Neeraja , Puius, Yoram A , Azar, Marwan M , Tsai, Helen , Vergidis, Paschalis , Harris, Courtney E , Anjan, Shweta , Barros, Nicolas , Belga, Sara , Czeresnia, Jonathan M , Ince, Dilek , Luk, Alfred , Majeed, Aneela , Multani, Ashrit , Obeid, Karam M , Swaminathan, Neeraja , Majeed, Aneela

Mayo Clinic

Open Forum Infectious Diseases | February 14, 2023 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/ofid/ofad081 | PMID 36861087 Get It

Abstract The field of transplant infectious diseases is rapidly evolving, presenting a challenge for clinical practice and trainee education. Here we describe the construction of transplantid.net, a free online library, crowdsourced and continuously updated for the dual purpose of point-of-care evidence-based management and teaching.
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, Clifford R. , Wiste, Heather J. , Figdore, Daniel J. , Schwarz, Christopher G. , Lowe, Val J. , Ramanan, Vijay K. , Vemuri, Prashanthi , Mielke, Michelle M. , Knopman, David S. , Graff‐Radford, Jonathan , Kantarci, Kejal , Gunter, Jeffrey L. , Therneau, Terry M. , Petersen, Ronald C. , Knopman, David S. , Figdore, Dan J, Schwarz, Christopher G , Ramanan, Vijay K , Vemuri, Prashanthi , Mielke, Michelle M , Graff-Radford, Jonathan , Kantarci, Kejal , Cogswell, Petrice M , Jack, Clifford R , Figdore, Daniel J , Algeciras‐Schimnich, Alicia , Boeve, Bradley F. , Cogswell, Petrice M. , Senjem, Matthew L.

Mayo Clinic

Brain | February 13, 2023 | Volume: 146 | Issue: 5 | Pages: 2029-2044

10.1093/brain/awad042 | PMID 36789483 Get It

Abstract Staging the severity of Alzheimer’s disease pathology using biomarkers is useful for therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face validity; however, this would be more practical with plasma biomarkers. Our objectives were, first, to examine approaches for staging amyloid and tau PET and, second, to examine prediction of amyloid and tau PET stages using plasma biomarkers. Participants (n = 1136) were enrolled in either the Mayo Clinic Study of Aging or the Alzheimer’s Disease Research Center; had a concurrent amyloid PET, tau PET and blood draw; and met clinical criteria for cognitively unimpaired (n = 864), mild cognitive impairment (n = 148) or Alzheimer’s clinical syndrome with dementia (n = 124). The latter two groups were combined into a cognitively impaired group (n = 272). We used multinomial regression models to estimate discrimination [concordance (C) statistics] among three amyloid PET stages (low, intermediate, high), four tau PET stages (Braak 0, 1–2, 3–4, 5–6) and a combined amyloid and tau PET stage (none/low versus intermediate/high severity) using plasma biomarkers as predictors separately within unimpaired and impaired individuals. Plasma analytes, p-tau181, Aβ1–42 and Aβ1–40 (analysed as the Aβ42/Aβ40 ratio), glial fibrillary acidic protein and neurofilament light chain were measured on the HD-X Simoa Quanterix platform. Plasma p-tau217 was also measured in a subset (n = 355) of cognitively unimpaired participants using the Lilly Meso Scale Discovery assay. Models with all Quanterix plasma analytes along with risk factors (age, sex and APOE) most often provided the best discrimination among amyloid PET stages (C = 0.78–0.82). Models with p-tau181 provided similar discrimination of tau PET stages to models with all four plasma analytes (C = 0.72–0.85 versus C = 0.73–0.86). Discriminating a PET proxy of intermediate/high from none/low Alzheimer’s disease neuropathological change with all four Quanterix plasma analytes was excellent but not better than p-tau181 only (C = 0.88 versus 0.87 for unimpaired and C = 0.91 versus 0.90 for impaired). Lilly p-tau217 outperformed the Quanterix p-tau181 assay for discriminating high versus intermediate amyloid (C = 0.85 versus 0.74) but did not improve over a model with all Quanterix plasma analytes and risk factors (C = 0.85 versus 0.83). Plasma analytes along with risk factors can discriminate between amyloid and tau PET stages and between a PET surrogate for intermediate/high versus none/low neuropathological change with accuracy in the acceptable to excellent range. Combinations of plasma analytes are better than single analytes for many staging predictions with the exception that Quanterix p-tau181 alone usually performed equivalently to combinations of Quanterix analytes for tau PET discrimination.
Arthroscopic-Assisted Anterior Glenoid Reconstruction Using Nonrigid Fixation With Distal Tibia Osteochondral Allograft
Riccio, Cory A., Tokish, John M. , Kilcoyne, Kelly G. , Hoyt, Benjamin W , LeClere, Lance E. , Dickens, Jonathan F.

Mayo Clinic

Video Journal of Sports Medicine | February 10, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.1177/26350254221131053 | PMID 40308546 Get It

Introduction: Traumatic anterior glenohumeral instability events result in a capsulolabral (Bankart lesion) and/or osseous injury with subsequent attritional bone loss, particularly with recurrence. Up to 88% of patients with recurrent instability experience glenoid bone loss, which predisposes to future dislocations and subluxations, even with arthroscopic capsulolabral repair. The surgical management of glenoid bone loss includes a number of different techniques such as the Latarjet or coracoid transfer as well as other osseous and osteoarticular autografts and allografts. However, operative management of shoulder instability has increasingly shifted toward arthroscopic approaches with preservation of anatomy when possible. Indications: Arthroscopic-assisted allograft distal tibia bone block augmentation to the anterior glenoid is indicated for revision anterior glenohumeral instability procedures with anterior bone loss and in primary cases of anterior instability with critical bone loss. Technique: Our technique for nonrigid arthroscopic anterior glenoid reconstruction with allograft distal tibia and anterior labral repair is performed preferentially in the lateral position without necessitating patient repositioning. The preplanned tibial bone block is prepared on a back table prior to the arthroscopic procedure. After creation of portals and elevation of labral tissue, a guide and drill are used to introduce a retrograde reamer which is deployed to create a perpendicular edge for apposition of the allograft tibia. The bone block is then introduced through a rotator interval portal by pulling sutures retrograde through glenoid bone tunnels and is secured to the prepared surface medial to the liberated labrum. The articular surface of the graft and glenoid are aligned and suture-based fixation is used to compress the bone block against the native glenoid. The anterior labral tissue is then mobilized over the graft and repaired to the native glenoid when possible. Description/Conclusion: The benefits of allograft tibia augmentation for anterior instability with glenoid bone loss include an anatomic joint surface restoration including articular cartilage, lack of donor site morbidity, and a minimally invasive arthroscopic approach. When performed arthroscopically and with nonrigid fixation, this technique permits concurrent anterior labral repair and anatomic reconstruction, safe graft passage without necessity of a far medial portal, and expeditious return to function.
Exploring Intra-arterial Contrast Administration for Intraoperative Imaging Using a Swine Model
Poe, Kelly, Stonko, David P. , Edwards, Joseph , Morrison, Jonathan J. , Morrison, Jonathan J , Stonko, David P , Treffalls, Rebecca N. , Abdou, Hossam , DeMartino, Randall R. , Ptak, Thomas

Mayo Clinic

Angiology | February 8, 2023 | Volume: 76 | Issue: 9 | Pages: 833-840

10.1177/00033197231155225 | PMID 36753679 Get It

Intraoperative computed tomography (CT) imaging with endovascular delivery of intra-arterial (IA) contrast could potentially provide higher attenuation with lower contrast volumes than intravenous (IV) administration. We aimed to compare IA and IV contrast use for organ-specific CT abdominal imaging. Five anesthetized swine had external jugular and brachial artery access with ascending aortic pigtail placement. An IV protocol was 100 mL at 5 mL/sec over 20 sec vs 50 mL of IA contrast at 5 mL/sec over 10 sec. Region-of-interest markers were applied to anatomical regions to measure attenuation (HU) over time. IA and IV contrast protocols achieved adequate aortic opacification (IA, 455 ± 289 vs IV, 450 ± 114 HU). The IA contrast aortic attenuation curve reached peak attenuation compared with IV contrast (IA, 8 vs 23 sec; P < .001). Time to peak attenuation was similar between IA and IV contrast in the portal vein (IA, 38 vs IV, 42 sec, P = .25). IA administration achieved a superior contrast-to-noise ratio (CNR) in less time compared with IV (R 2 = .94; P < .001). IA contrast achieved adequate opacification with less bolus broadening and a superior CNR compared with IV contrast while using a smaller contrast volume for directed organ-directed imaging.
Baseline characteristics of the North American prodromal Synucleinopathy cohort
Lim, Miranda M. , Keil, Allison , Postuma, Ronald B. , Pelletier, Amélie , Gagnon, Jean‐François , Louis, Erik K. St. , Forsberg, Leah K. , Fields, Julie A. , Huddleston, Daniel E. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Summers, Rebekah L. S. , Ligman, Brittany R. , MacKinnon, Colum D. , Elliott, Jonathan E , Lim, Miranda M , Keil, Allison T , Postuma, Ronald B , Gagnon, Jean-François , St Louis, E K , Fields, Julie A , Huddleston, Daniel E , Bliwise, Donald L , Howell, Michael J , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Shprecher, David , Lee-Iannotti, Joyce K , Boeve, Brad , Ju, Yo-El S , Elliott, Jonathan E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 8, 2023 | Volume: 10 | Issue: 4 | Pages: 520-535

10.1002/acn3.51738 | PMID 36751940 Get It

Abstract Objective Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic‐based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment. Methods Participants ≥18 years of age with overnight polysomnogram‐confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function. Results Outcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use ( n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden ( n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ‐9; 39.3% and 31%, respectively). Interpretation These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.
Cephalomedullary Nailing of Unstable Geriatric Intertrochanteric Fractures on a Traction Table Combined With Percutaneous Reduction Techniques Is Safe and Results in a Low Rate of Cutout
Somasundaram, V. , Owen, Aaron R. , Cross, William W., Sems, S.A. , Yuan, Brandon J. , Somasundaram, Vivek, Yuan, Brandon , Somasundaram, Vivek, Hidden, Krystin A. , Barlow, Jonathan D.

Mayo Clinic

Journal of Orthopaedic Trauma | February 7, 2023 | Volume: 37 | Issue: 7 | Pages: 323-329

10.1097/bot.0000000000002577 | PMID 36750432 Get It

Objectives: To describe a reproducible technique for reduction assessment and percutaneous reduction of unstable intertrochanteric fractures treated with a cephalomedullary nail on a traction table. Design: Retrospective cohort study. Setting: Level-1 trauma center. Patients: Two-hundred 20 consecutive patients with intertrochanteric fractures. Intervention: Initial closed reduction performed on a traction table. Accessory incisions were used to facilitate a reduction in 77 patients (35%). All fractures were stabilized with a cephalomedullary nail. Main Outcome Measurements: Radiographic outcome including union, cutout, and fracture collapse (FC). Surgical outcomes including infection and hematoma were also reported. Results: Mechanical complications (nonunion, cutout, and varus collapse) occurred in 8.8% of patients at 1 year. Eleven of 13 patients who developed these complications had either suboptimal implant placement (tip-to-apex distance >25 mm) or a varus reduction. There was no difference in the incidence of reoperation, nonunion, lag screw cutout, or posttraumatic arthritis based on the use of an accessory incision for fracture reduction. There was a significant increase in FC in patients who received an accessory incision (6.8 mm vs. 5.4 mm, P = 0.04). One patient (1%) developed a hematoma in the accessory incision cohort, and 1 patient (0.7%) who did not have an accessory incision developed a postoperative infection. Conclusions: The current study suggests utilization of accessory incisions assist in reduction is safe and is associated with a low rate of complications. The surgeon should prioritize fracture reduction and optimal implant placement and not hesitate to use an accessory incision to assist with fracture reduction. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
ABCB7 deficiency causes ferroptosis in peripheral T cells
Lehrke, Michael Jonathan , Belmonte, Paul , Kennedy, Madeleine, Rajcula, Matthew, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 98.42-98.42

10.4049/jimmunol.206.supp.98.42 Get It

Abstract ABCB7 exports iron-sulfur (Fe-S) clusters from the mitochondria into the cytoplasm. Conditional deletion of ABCB7 revealed that it is required for peripheral T cell homeostasis. CD4-cre ABCB7 cKO mice have normal thymic development, but a severe reduction in peripheral T cell numbers. A majority of the peripheral T cells in the ABCB7 cKO mice were recent thymic emigrants (RTEs), indicating a loss of more mature T cells in the periphery. T cell maturation markers were found to be normal and stimulation of ABCB7 cKO RTEs revealed normal levels of TNFα production. These data indicate that the loss of peripheral T cells in CD4-cre ABCB7 cKO mice was not due to a defect in development or maturation but a defect in peripheral homeostasis. ABCB7-deficient T cells did not have evidence of elevated apoptosis. We demonstrated iron accumulation was occurring in ABCB7-deficient peripheral T cells using the metal-specific dye Phen Green SK. Additionally, lipid peroxides levels were elevated in the ABCB7 cKO T cells. Lipid peroxides are a hallmark of ferroptosis, an iron-dependent form of regulated cell death. Expression of GPX4, the master regulator of ferroptosis, was normal in ABCB7 cKO T cells. In addition, levels of glutathione, which counteracts lipid peroxides were found to be normal, indicating the ferroptosis protection pathway was intact and that the iron overload was causing ferroptosis. Interestingly, treatment with the iron chelator deferoxamine did not rescue peripheral T cells in the CD4-cre ABCB7 cKO mice. Vitamin E, a potent antioxidant, also failed to rescue peripheral T cell homeostasis. Thus, ABCB7 is required to maintain iron homeostasis and its loss leads to peripheral T cell ferroptosis.
Patient Satisfaction and Pain Relief After Deep Peroneal Nerve Neurectomy for Midfoot Arthritis: A Preliminary Short Report
Iturregui, Jose M. , Haupt, Edward T. , Kraus, Jonathan C. , Shi, Glenn G. , Wilke, Benjamin K. , Shi, Glenn G , Haupt, Edward

Mayo Clinic

Foot & Ankle International | February 6, 2023 | Volume: 44 | Issue: 3 | Pages: 171-177

10.1177/10711007221149028 | PMID 36744743 Get It

Background: The deep peroneal nerve (DPN) plays a role in afferent nociceptive dorsal midfoot joint pain perception. DPN neurectomy for treatment of symptomatic dorsal midfoot osteoarthritis allows early mobilization and weightbearing. The purpose of our study was to evaluate the patient satisfaction and pain relief after DPN neurectomy for treatment of chronic dorsal midfoot pain due to osteoarthritis. Methods: In this retrospective, IRB-approved, questionnaire-based study, we evaluated 48 patients (55 feet) with an average follow-up of 35.1 (range, 16-51) months who underwent DPN neurectomy at our institution between September 2017 and February 2021. There were 38 women and 10 men, 41 unilateral (22 right, 19 left) and 7 bilateral procedures, with an average age of 67.8 (range, 35-88) years at the time of surgery. A questionnaire that included questions regarding postsurgical dorsal midfoot pain relief, surgical result satisfaction, and current functional limitations was administered via telephone. Demographic information, patient responses, and complications were recorded. Results: Of the 48 patients, 80.8% were satisfied with the result of the surgery in relieving their dorsal midfoot pain, 84.6% would repeat the surgery under the same circumstances, 83.8% would recommend the surgery to a friend, 10.4% reported they wish they had undergone arthrodesis, 91.7% reported pain relief in the first 6 months, and 55.6% reported current activity limitations. Six feet (10.9%) underwent a second procedure with an average postoperative time of 20.5 (range, 1-36) months. Complications included 1 hematoma and deep wound infection, 1 DPN neuroma and superficial peroneal nerve entrapment, and 4 patients with inadequate pain relief. Conclusion: In this cohort, DPN neurectomy appeared to be a reasonable surgical alternative to arthrodesis for the management of chronic dorsal midfoot pain due to midfoot osteoarthritis after failed nonoperative management. Level of Evidence: Level IV, retrospective case series.